Business Wire · Jul 2025
MoU to industrialize and scale Sensible’s cell-based mRNA platform, with the goal of enabling clinical-grade production by 2026 and expanding manufacturing support across the US, UK, and Europe.
Unlocking the next generation of mRNA medicines
Company research
Public company, workplace, funding, and market signals
Overview
Sensible Biotechnologies is a cell-based mRNA therapeutics platform company building living-cell manufacturing for high-purity, low-immunogenicity mRNA for pharma/biotech partners. Public sources conflict on headquarters (Claymont, Delaware vs Oxford, UK); the clearest operating footprint is Boston, Oxford, and Bratislava.
Primary product
Cell-based mRNA design, optimization, and manufacturing platform
Founded
2021
Headquarters
Claymont, Delaware, United States
Team size
11-50 employees
Industry
Biotechnology Research
Sub-industry
cell-based mRNA therapeutics
Offices
Boston, Massachusetts, United States
Oxford, United Kingdom
Bratislava, Slovakia
Cambridge, Massachusetts, United States
Business model
B2B platform
strategic partnerships
co-development
manufacturing enablement
Funding
Stage
Seed-stage / early-stage venture-backed
Total raised
$13M
Latest round
Grant · Sep 2025
People & investors
Leadership
CEO & Co-Founder
Chief Scientific Officer & Co-Founder
Chief Technology Officer
Head of People
Lab Director, Principal Computational Scientist
VP Finance
Director of Slovak Laboratory
Head of Partnerships & External Affairs
Work & culture
Mission-driven, science-heavy, and cross-border; public posts emphasize collaboration, hiring growth, equal opportunity, and building a resilient biomanufacturing platform across the US, UK, and Slovakia.
Compensation
Public compensation evidence is limited. One Bratislava Associate Scientist posting advertised full-time compensation of EUR 1,200-1,800, commensurate with experience and qualifications; broader comp bands are not public.
Benefits
equal opportunities
comprehensive training in diverse laboratory techniques
vibrant work environment
annual company retreat in Edinburgh
Product & market
Pricing
B2B platform/co-development and manufacturing services; public pricing is not disclosed.
Differentiators
- —cell-based production instead of IVT
- —low-immunogenicity, high-purity mRNA
- —scalable manufacturing
- —AI-assisted optimization with NVIDIA
- —vertically integrated design-to-manufacture platform
- —resilient local supply-chain approach
Technology
NVIDIA BioNeMo
NVIDIA NIM microservices
NVIDIA DGX Cloud
Hopper H100 GPUs
Python
Docker
Kubernetes
CI/CD
cloud-native infrastructure
LIMS
lab automation
Microsoft
cell engineering
computational biology
precision fermentation
Customers
pharma companies
biotech companies
research groups
Competitors
Twist Bioscience
Parse Biosciences
Ansa Biotechnologies
Sino Biological
GenScript
Scale & contact
Estimated monthly visits
4K
Latest news
Business Wire · Jun 2025
Announced NVIDIA-powered AI/molecular design workflow using BioNeMo, NIM microservices, and DGX Cloud; the company said optimization cycles fell from 15 days to 1 day.
Forbes · Apr 2024
Forbes profiled the company and its founders, describing the cell-based mRNA manufacturing thesis and noting roughly $10M raised at that time.
PR Newswire · Apr 2023
Pre-seed financing led by BlueYard Capital with participation from Y Combinator, Amino Collective, Civilization Ventures, Recode Health Ventures, ZAKA, and angel investors; proceeds were to scale the platform.
PR Newswire · Apr 2023
Announced a partnership with Ginkgo Bioworks to develop a novel mRNA manufacturing platform using living cells.
Jobs and careers at Sensible Biotechnologies
0 jobs at Sensible Biotechnologies
No open positions
Check back later for new openings